WO2006051937A1 - ヘテロ5員環誘導体 - Google Patents
ヘテロ5員環誘導体 Download PDFInfo
- Publication number
- WO2006051937A1 WO2006051937A1 PCT/JP2005/020791 JP2005020791W WO2006051937A1 WO 2006051937 A1 WO2006051937 A1 WO 2006051937A1 JP 2005020791 W JP2005020791 W JP 2005020791W WO 2006051937 A1 WO2006051937 A1 WO 2006051937A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lower alkyl
- substituent
- compound
- pharmaceutically acceptable
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Definitions
- the present invention relates to a hetero 5-membered ring derivative and a pharmaceutical composition containing the same, particularly an antibody production inhibitor, and a Z or dihydrorotate dehydrogenase inhibitor.
- immunosuppressive agents such as azathioprine, corticoids, cyclosporin A and tacrolimus have been developed and put into practical use and are used for the prevention and treatment of organ- or tissue-transplant rejection and graft-to-host reactions caused by bone marrow transplantation. However, these are not always satisfactory in terms of effects and side effects.
- allergic diseases such as atopic dermatitis, allergic rhinitis, bronchial asthma, and allergic conjunctivitis have been increasing worldwide in recent years and have become major problems.
- Conventional anti-allergic agents are inhibitors of the release of chemical mediators from mast cells, receptor inhibitors of released chemical mediators, or inhibitors of allergic inflammatory reactions. Is also a symptomatic treatment and is not a treatment for fundamental allergic diseases.
- DHODH Dihydrorotate dehydrogenase
- Rapid cell growth requires DNA and RNA synthesis, protein glycosylation, membrane lipid biosynthesis, and new pyrimidine biosynthesis for nucleic acid chain repair DHODH-catalyzed step Is the rate-limiting step of pyrimidine biosynthesis.
- DHODH is rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, uveitis, myasthenia gravis, bronchial asthma, atopic dermatitis, psoriasis, virus infection, bacterial infection, bacteria Infectious disease, parasitic infection, cancer, rejection in transplantation It is known that it is related to graft-versus-host disease, and DHODH inhibitors are useful for the treatment or prevention of the above-mentioned diseases (see Non-Patent Documents 1 to 5).
- Patent Documents 1 to 6 disclose biphenyl compounds having thiazolidine or oxazolidine rings having anti-inflammatory action, anti-allergic action and the like.
- Patent Documents 1 to 4 describe compounds in which the position corresponding to the W group of the compound represented by the formula (I) which is the compound of the present invention is hydrogen, lower alkoxy, halogeno lower alkoxy or the like. All the groups corresponding to I ⁇ to R 4 are hydrogen, and the compounds of the present invention are not disclosed.
- Patent Document 5 specifically discloses a compound in which the substituent corresponding to ring A of the compound of the present invention is tetrahydronaphthyl, but does not disclose the compound of the present invention.
- Patent Document 6 describes a compound having a lower alkoxy at a position corresponding to the W group of the compound of the present invention. However, both are 4-oxo-2-thioxazolidine derivatives, and the compound of the present invention is disclosed. Not.
- Patent Document 1 Japanese Patent Laid-Open No. 2-62864
- Patent Document 2 Pamphlet of International Publication No. 2004Z024061
- Patent Document 3 US Patent Application Publication No. 2003Z0134885
- Patent Document 4 Special Table 2004-505958 Pamphlet
- Patent Document 5 International Publication No. 01Z016123 Pamphlet
- Patent Document 6 International Publication No. 03Z043998 Pamphlet
- Non-Patent Document 1 Immunopharmacology 2000, 47th, p. 63 -83
- Non-Patent Document 2 Immunopharmacology 2000, 47th, p. 27 3-289
- Non-Patent Document 3 Cancer Research 1986, 46th, p. 5014-50 19
- Non-patent literature 4 Biochemistry 1994, 33rd pp. 5268-5274
- Non-patent literature 5 Biochemical Pharmacology 2000, 60th pp. 339-342) Disclosure of the invention
- An object of the present invention is to provide a novel hetero 5-membered ring derivative, a pharmaceutical composition containing the same, an antibody production inhibitor, and a DHODH inhibitor.
- the present invention provides:
- R 2 , R 3 and R 4 are each independently hydrogen, halogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted.
- R 2 , R 3 and R 4 are each independently hydrogen, halogen, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted.
- R 5 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally having substituent, lower alkoxy, having substituent! /,
- R 6 is hydrogen, optionally substituted lower alkyl or optionally substituted V ⁇ cycloalkyl,
- X 3 is 0, S or NR 13 ,
- X 4 is CR 7 or N
- X 5 is CR 8 or N
- X 6 is CR 9 or N
- X 7 is CR 1G or N
- at least one of X 4 to X 7 is N and at least one other is not N
- R 7 to R 12 are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkyl
- R 13 and R 14 are each independently hydrogen, lower alkyl, lower alkoxycarbol or aryl lower alkyl;
- W is hydrogen, NR 15 R 16 , SR 17 , COR 18 , CONR 19 R 2 , OR 21 or a lower alkyl which may have a substituent.
- R 15 and R 16 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkyl, optionally substituted cycloalkyl, It may have a substituent, but it may be rubamoyl, it may have a substituent! /!
- Y 2 is CR 22 R 23 , S, O or NR 24 ,
- Y 3 is 0, S or H
- R 22 and R 23 are each independently hydrogen or lower alkyl
- R 24 may be hydrogen, substituted, or may be lower alkyl or substituted.
- V ⁇ cycloalkyl V ⁇ cycloalkyl
- X 1 is CR 2
- X 2 is N or CR 4
- W is hydrogen
- W is OR 21 ), a pharmaceutically acceptable salt thereof, or a solvate thereof .
- W is NR 15 R lt3 , the compound according to the above (1) or (2), its pharmaceutically acceptable Salts or solvates thereof.
- R 15 and R 16 are each lower alkyl, heterocyclic lower alkyl, lower grade Aruke - a le or cycloalkyl, (3) compounds according, or a pharmaceutically acceptable salt or Their solvates.
- a compound according to any one of the above, a pharmaceutically acceptable salt thereof or a solvate thereof is provided.
- a pharmaceutical composition comprising the compound according to any one of (1) to (11) above, a pharmaceutically acceptable salt thereof, or a solvate thereof. Is to provide.
- the present application is characterized by administering compound (I), a method for suppressing an immune reaction, a method for suppressing antibody production, and a method for treating and preventing Z or tumor of allergic diseases and Z or tumors Provide a method.
- Yet another embodiment provides the use of Compound (I) for the manufacture of a medicament for the suppression and immune production of antibodies, suppression of antibody production, and treatment and Z or prevention of allergic diseases and Z or tumors.
- the compound of the present invention exhibits a strong antibody production inhibitory action and a Z or DHODH inhibitory action.
- halogen includes fluorine, chlorine, bromine and iodine.
- “Lower alkyl” includes linear or branched alkyl having 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 3 carbon atoms, and includes, for example, methyl, ethyl, n-pro Pyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n —Nole and n-decyl are listed.
- the substituent of "lower alkyl having a substituent” may be halogen; hydroxy; lower alkoxy; lower alkyloxy; lower alkylthio; lower alkyloxy; lower alkyl- Carboxy; lower alkoxy carb; mercapto; lower alkylthio; amino; lower alkylamino; isylamino; Forced rubamoyl; thiocarbamoyl; lower alkylthio-powered rubamoyl; arylylthio-powered rubamoyl; substituted with lower alkyl or lower alkoxy!
- Cycloalkyl substituted with lower alkyl or lower alkoxy; cycloalkyl alkenyl; cyano; nitro; lower alkyl sulfoxy; aryl sulfonyloxy; norogen, hydroxy, lower alkyl, lower Alkoxy, acyl, carbo Xyl and lower alkoxy carbonates
- a phenyl optionally substituted with one or more selected groups; a nonogen, a hydroxy, a lower alkyl, a lower alkoxy, an acyl, a carboxyl and a lower alkoxy carbo
- a hetero ring which may be substituted with one or more groups and may be condensed with a benzene ring (particularly a furan ring, a thiophene ring, a tetrahydropyran ring, a dioxane ring, etc.) and the like, preferably a halogen; Hydroxy; acyl; carboxy; lower alk
- the lower alkyl part of “lower alkyl”, “lower alkoxy lower alkyl” and “lower alkylenedioxy” is the same as the above “lower alkyl”.
- the substituent of “-l” is the same as the substituent of the above-mentioned “lower alkyl having a substituent”.
- the "lower alcohol” is a straight chain having 2 to 10 carbon atoms, preferably 2 to 8 carbon atoms, more preferably 3 to 6 carbon atoms, having one or more double bonds at any position. Includes branched alkenyl. Specifically, bur, probe, isoprobe, butur, isobuteninore, preninore, butageninore, penteninore, isopenteninore, pentageninore, hexenore, isohexenyl, hexagenyl, heptenyl, octenyl , Nonenyl, decenyl and the like.
- “Lower alkynyl” includes linear or branched alkyl having 2 to 10 carbon atoms, preferably 2 to 8 carbon atoms, more preferably 3 to 6 carbon atoms. Examples include ethur, propininole, butyninole, pentinore, hexininore, heptininore, octininore, nonininore and decynyl. These have one or more triple bonds at any position, and may further have a double bond.
- lower alkyl part of “lower alkyloxy” and “lower alkylthio” is the same as the above “lower alkyl”.
- Asil means a linear or branched chain aliphatic acyl having 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, more preferably 1 to 4 carbon atoms, 4 to 9 carbon atoms, preferably Includes cycloaliphatic asilyl and aroyl having 4 to 7 carbon atoms.
- the substituent of “has a substituent” may be the same as the substituent of the above-mentioned “has a substituent, may be lower / lower alkyl”, and further, aroyl is a lower alkyl. May be substituted as a substituent. Unsubstituted acyl is preferred.
- acyl portion of “acylamino” and “acyloxy” is the same as the above “acyl”.
- “Cycloalkyl” is a carbocyclic ring having 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms, and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. To do.
- Examples of the substituent of “may have a substituent and cycloalkyl” include the lower alkyl and the same substituents as those of the above-mentioned “having a substituent and may be lower alkyl”. And one or more arbitrary positions may be substituted. Preferred are lower alkyl, halogen, hydroxy and the like.
- cycloalkyl part of “cycloalkyloxy” is the same as the above “cycloalkyl”.
- “Cycloalkenyl” includes those having one or more double bonds at any position in the ring of the cycloalkyl, specifically, cyclopropyl, cyclobutyl, cyclopentenyl, And cyclohexenol, cycloheptynyl, cyclooctynyl, cyclohexagel and the like.
- Substituents of “optionally substituted amino” include: hydroxy; lower alkyl; lower alkenyl; lower alkynyl; asil; cycloalkyl; strength rubamoyl; lower alkylcarbamoyl; sulfamoyl; Famoyl, lower alkoxy carb; lower alkyl sulphone; and cyano; having a substituent!
- the “optionally substituted rubamoyl” includes alkamoyl optionally substituted with lower alkyl, lower alkyl, lower alkyl, cycloalkyl, aryl, and the like.
- the "aryl” includes a film, naphthyl, anthryl, phenanthryl, indul and the like, and a file is particularly preferable.
- Substituents of “having a substituent, may be aryl” include halogen; hydroxy; lower alkyl which may be substituted with one or more groups each selected from the following substituent group a force Kill, lower alkoxy, lower alkylthio, lower alkenyl, lower alkenyloxy, lower alkenylthio, lower alkynyl, lower alkynyloxy, lower alkynylthio, cycloalkyl, cycloalkyloxy, asil, acyloxy, lower alkoxy groups , Lower alkoxycarbol, acyl, ami-substituted lower alkylsulfol, lower alkylsulfoloxy; carboxy; amidino; guazino; nitro; substituent group a force one or more groups
- the substituent group ⁇ is a group consisting of halogen, hydroxy, lower alkoxy, acyl, carboxy, lower alkoxy carbo- yl, cycloalkyl and phenyl.
- aryl part of “aryl reel”, “aryl reel lower alkyl”, “aryl reel rumoyl” and “aryl reel ruber moyl” is the same as the above “aryl”.
- the substituent of “may have a substituent or arylaryl” is the same as that of the above “V having a substituent or may be aryl”.
- Heterocycle includes a 5-membered or 6-membered heterocycle having one or more heteroatoms arbitrarily selected from 0, S and N, specifically a pyrrole ring, imidazole Ring, pyrazole ring, pyridine ring (4 pyridyl, etc.), pyridazine ring, pyrimidine ring, pyrazine ring, triazole ring, tetrazole ring, triazine ring, isoxazole ring, oxazole ring, oxadiazole ring, isothiazole ring, thiazole ring , Thiadiazole rings, furan rings (such as 2 furyl and 3-furyl) and thiophene rings (such as 3-chenyl) Mouth ring, tetrahydropyran ring, dihydropyridine ring (1,2-dihydropyridyl, etc.), dihydropyridazine ring (2,3-d
- the substituent of “having a substituent may be a heterocycle” is the same as the above-mentioned “having a substituent and may be a aryl”, and preferably a lower alkyl, a lower alkoxy or a lower alkyl. Or carboxy or the like.
- heterocyclic portion of “heterocyclic lower alkyl” is the same as the above “heterocycle”.
- “compound (I)” is also included, and in this case, a pharmaceutically acceptable salt of each compound that can be produced is also included.
- “Pharmaceutically acceptable salts” include, for example, salts of mineral acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid; formic acid, acetic acid, tartaric acid, lactic acid, quenate, fumar Salts of organic acids such as acid, maleic acid and succinic acid; Salts of organic bases such as ammonia, trimethylammonium and triethylammonium; Salts of alkali metals such as sodium and potassium or calcium and magnesium And alkaline earth metal salts.
- the compounds of the present invention include solvates (preferably hydrates) thereof.
- Solvates include organic solvents and solvates with Z or water. When forming hydrates, you can coordinate with any number of water molecules.
- the compounds of the present invention include all isomers thereof (ketenols isomers, diastereoisomers, optical isomers, rotational isomers, etc.).
- Hal is halogen
- L and Z are one of dihydroxyboryl, dilower alkylboryl or dilower alkoxyboryl and the other is halogen or OSO (C F
- a formyl group is introduced into a known compound or a compound (VI) obtained from a known compound by a conventional method.
- alkyl lithium for example, n -butyl lithium, tert-butyl lithium, sec butyl lithium, etc.
- lithium diisopropylamide Lithium hexamethyldisilazide and the like
- the target compound (V) is obtained by reacting with an aldehyde compound such as N, N-dimethylformamide, N-methylformaldehyde or the like.
- Obtained compound (V) from a known compound or a known compound in a suitable solvent eg, N, N dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, toluene, etc.
- a suitable solvent eg, N, N dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, toluene, etc.
- the target compound ( ⁇ a) is obtained.
- reaction may be performed in the presence of sodium hydride, potassium hydride, t-butoxypotassium, t-butoxysodium, acetic acid, hydrochloric acid, sulfuric acid, p-toluenesulfonic acid and the like.
- compound (IIIa) is reacted with compound (II) to obtain the compound (Ia) of the present invention.
- a suitable solvent eg, benzene, toluene, N, N dimethylformamide, dimethoxyethane, tetrahydrofuran, dioxane, ethanol or methanol
- Palladium catalyst for example, Pd (PPh), PdCl (P
- Basic conditions bases such as KPO, NaHCO, NaOEt, NaCO, KCO
- the compound of the present invention (Ia) is obtained by reacting at room temperature to about 180 ° C. for about 5 minutes to about 48 hours, preferably about 0.5 hours to about 18 hours.
- One of the substituents L and Z in the compound to be reacted with each other is a Suzuki reaction (Chemical Communication 1979, 866, Journal of Organic Synthesis, 1993, 51st, No. 11, pages 91 to 100). Any boryl group that can be applied to (p.) May be used, and dihydroxyboryl is preferred.
- the other can be any leaving group applicable to the Suzuki reaction, such as halogen or OSO (C F) (where q is an integer from 1 to 4), etc.
- halogen, trifluoromethanesulfonyloxy and the like are preferable, and bromine, iodine or OTf is most preferable.
- Substituents other than L and Z may be any groups other than groups that do not adversely affect the Suzuki reaction, such as halogen and OSO (C F) (where q is an integer of 1 to 4).
- the target compound of the present invention is the compound (Ib) whose broken line is a single bond
- it can be obtained by reducing the compound (Ia) obtained by the above-mentioned step by a conventional method.
- a transition metal catalyst such as noradium carbon, noradium black, Raney nickel, acid platinum, platinum black, rhodium-aluminum oxide, triphenylphosphine-rhodium chloride, palladium-barium sulfate, etc.
- a solvent tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, toluene, dichloromethane, ethyl acetate, etc.
- the reaction may be reduced by reaction for about 0.5 hours to about 2 hours. If necessary, it can be carried out in the presence of a deoxidizer (triethylamine, pyridine, potassium carbonate, sodium hydrogencarbonate, sodium acetate, etc.).
- lithium aluminum hydride, sodium borohydride, sodium triacetoxyhydrogen hydride, tin chloride, magnesium Z ethanol, triphenylphosphine, sodium Z ethanol, sodium cyanoborohydride Z trisalt ⁇ titanium, borane Z Reduction can be performed in a suitable solvent (tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, toluene, dichloromethane, chloroform, etc.) using a commonly used reducing agent such as trifluoroacetic acid, diisobutylaluminum, and idride. is there.
- the compounds of the present invention thus obtained all have high activity and are useful as pharmaceuticals, but the following compounds are particularly preferred.
- X 1 is CR 2
- X 2 is CR 4 and R ⁇ R 2 , R 3 and R 4 each independently have hydrogen, halogen, substituent, and may be lower alkyl or A compound having a substituent, which is lower alkyloxy (hereinafter, X is X-1) (hereinafter, X is X-1)
- X 1 is CR 2
- X 2 is CR 4
- R 2 , R 3 and R 4 are each independently hydrogen, halogen, lower alkyl or lower alkoxy, Selected from R 2 , R 3 and R 4
- R 6 is hydrogen, lower alkyl, lower alkoxycarbonyl lower alkyl, carboxy lower alkyl or cycloalkyl (hereinafter, R 6 is R 6 — 1), R 6 is hydrogen or lower alkyl ( In the following, R 6 is assumed to be R 6 —2, and the compound, ring A is
- ring A is A-2
- ring A is A-3
- ring A is A-4
- R 1 & and R lb are each independently hydrogen, lower alkyl, furyl lower alkyl, lower alkyl or cycloalkyl, and other symbols are as defined in 1) above) (hereinafter, A compound wherein ring A is A-5),
- Y 1 is SO, Y 2 is CH, Y 3 is H (hereinafter, Y is Y-4)
- the dashed line is a double bond
- R 5 is hydrogen
- X 1 , X 2 A compound in which the combination of Y 2 and Y 3 (X, R 6 , A, Y) is as follows.
- the compound of the present invention has an antibody production inhibitory action, particularly an IgE production inhibitory action, such as rejection of organ or tissue transplantation, transplantation immunity (acute or chronic GVHD), autoimmune disease (especially organ nonspecific autoimmunity). Disease), mixed connective tissue disease (MCTD), ischemia-reperfusion injury, ulcerative colitis, systemic lupus erythematosus, myasthenia gravis, generalized progressive scleroderma, rheumatoid arthritis, interstitial Cystitis, Hashimoto's disease, Graves' disease, autoimmune hemolytic anemia, idiopathic thrombocytopenia purpura, Goodpastiia syndrome, atrophic gastritis, aplastic anemia, Addison's disease, pemphigus, pemphigoid, lens uveitis , Sympathetic ophthalmitis, primary biliary cirrhosis, active chronic hepatitis, Jujuren's
- immunosuppressants can be used as a treatment for chronic renal failure induced by non-immunological mechanisms (Kidney International vol.54 (1998), pp. 1510). —1519, Kidney International vol.55 (199 9), pp. 945-955), the compound of the present invention can also be a therapeutic agent for nonimmune chronic renal failure.
- the compound of the present invention has a DHODH inhibitory action
- diseases associated with the action of DHODH such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, lens uveitis, severe muscle Asthenia, bronchial asthma, atopic dermatitis, psoriasis, viral infection, bacterial infection, bacterial infection, parasitic infection, transplant rejection, graft-versus-host disease, cancer (e.g., myeloma , Myeloma), lymphoma, leukemia, etc.).
- diseases associated with the action of DHODH such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, lens uveitis, severe muscle Asthenia, bronchial asthma, atopic dermatitis, psoriasis, viral infection, bacterial infection, bacterial infection, parasit
- the compound of the present invention When the compound of the present invention is administered as an antibody production inhibitor, DHODH inhibitor, antiallergic agent, immunosuppressive agent or anticancer agent, it can be administered either orally or parenterally.
- Oral administration may be prepared and applied to a commonly used dosage form such as tablets, granules, powders, capsules, pills, solutions, syrups, buccals, or sublinguals according to conventional methods.
- any commonly used dosage forms such as injections such as intramuscular administration and intravenous administration, suppositories, percutaneous absorption agents, and inhalants can be suitably administered.
- oral administration is preferred.
- отное отное отное о ⁇ ное ком ⁇ онентs such as excipients, binders, wetting agents, disintegrants, lubricants, diluents and the like suitable for the dosage form are mixed with an effective amount of the compound of the present invention as necessary to obtain a pharmaceutical preparation. can do. In the case of an injection, it may be sterilized with an appropriate carrier to prepare a preparation.
- an excipient lactose, sucrose, glucose, starch, calcium carbonate or crystalline cellulose is used as a binder.
- Is methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, gelatin or polybutylpyrrolidone, and disintegrators are carboxymethyl cellulose, sodium carboxymethyl cellulose, starch, sodium alginate, agar powder, sodium lauryl sulfate, etc. Examples include talc, magnesium stearate or macrogol. As a suppository base, cacao butter, macrogol or methyl cell mouth can be used.
- a solubilizing agent, suspending agent, emulsifying agent, stabilizing agent, preservative, isotonic agent, etc. that are usually used are added as appropriate.
- the dose of the compound of the present invention as an antibody production inhibitor, a DHODH inhibitor, an antiallergic agent, an immunosuppressive agent or an anticancer agent takes into account the age, weight, type and degree of disease, route of administration, etc. of the patient. Although it is desirable to set the above, it is usually 0.05 to: LOOmgZkgZ ⁇ , preferably 0.1 to LOmgZkgZ ⁇ when orally administered to an adult.
- the force varies greatly depending on the route of administration, usually 0.005 to 10 mgZkgZ days, and preferably within the range of 0.01 to lmgZkgZ days. This should be administered once to several times a day.
- Human histiocytic lymphoma cell line was disrupted by ultrasound in homogenizing buffer (20 mM Tris-HCl, pH 7.4, containing 2 mM EDTA and protease inhibitor cocktail), and then 1,200 X Cell debris were removed by centrifugation at 4 ° C for 15 minutes at g. Furthermore, ultracentrifugation was performed twice at 120,000 Xg for 60 minutes and at 4 ° C to prepare a mitochondrial / microsomal fraction. The obtained fraction was subjected to protein quantification, adjusted to 10 mg / ml and measured. Stored frozen at -40 ° C until time.
- Reaction solution 50 mM Tris-HC1, pH 7.4, containing 0.1% Triton X—100, 1 mM KCN, 100 ⁇ M coenzyme Q10, 200 ⁇ M DCIP
- a 0.2 mg mitochondrial / microsomal fraction was added and preincubated at 37 ° C for 30 minutes.
- a substrate 5 mM DHO solution 201 final concentration 500 ⁇ was added and incubated at 37 ° C for 120 minutes, and then the absorbance at a measurement wavelength of 620 nm was measured.
- the inhibition rate of the compound at each concentration with respect to the change in absorbance due to the enzyme reaction was determined, and the concentration showing 50% inhibition (IC50 value) was calculated to evaluate the inhibitory activity of the compound. The results are shown in the table below.
- mice male, 8-10 weeks old
- Wistar rats male, 8-10 weeks old
- Japan SLC Japan SLC (Shizuoka) used.
- OVA ovalbumin
- lmg aluminum hydroxide gel
- the compound of the present invention was suspended in 0.5% methylcellulose and orally administered at 0.1 ml per mouse (dose 40 mgZkg). Administration was carried out for 10 consecutive days until the day before blood collection.
- mice serum was diluted with physiological saline to prepare a 2-fold dilution series, and this was injected into the back skin of Wistar rats that had been pre-treated with hair IJ 50 1 by one.
- a physiological saline solution containing OVAlmg and 5 mg of Evans blue dye was intravenously injected to induce passive skin anaphylactic reaction (PCA).
- PCA passive skin anaphylactic reaction
- mice 2 was the PCA titer.
- the anti-OVA IgE antibody titer of mice was 7 if the PCA reaction positive there serum is up to two 7-fold dilution. The results are shown in Table 5.
- the compounds of the present invention are useful as antibody production inhibitors, DHODH inhibitors, antiallergic agents, immunosuppressive agents, and Z or anticancer agents.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006544994A JPWO2006051937A1 (ja) | 2004-11-15 | 2005-11-14 | ヘテロ5員環誘導体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-330598 | 2004-11-15 | ||
JP2004330598 | 2004-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006051937A1 true WO2006051937A1 (ja) | 2006-05-18 |
Family
ID=36336602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020791 WO2006051937A1 (ja) | 2004-11-15 | 2005-11-14 | ヘテロ5員環誘導体 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2006051937A1 (ja) |
TW (1) | TW200626130A (ja) |
WO (1) | WO2006051937A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012109329A2 (en) | 2011-02-08 | 2012-08-16 | Children's Medical Center Corporation | Methods for treatment of melanoma |
US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513821A (ja) * | 1997-03-03 | 2001-09-04 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 炎症性疾患の治療に有用な小分子 |
WO2003006425A2 (en) * | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
WO2003030905A1 (fr) * | 2001-10-01 | 2003-04-17 | Shionogi & Co., Ltd. | Inhibiteur de la dihydroorotate deshydrogenase |
WO2004024061A2 (en) * | 2002-04-30 | 2004-03-25 | Merck & Co., Inc. | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
JP2004099586A (ja) * | 2002-05-21 | 2004-04-02 | Sumitomo Pharmaceut Co Ltd | ジヒドロオロテートデヒドロゲナーゼ阻害剤 |
WO2004028535A1 (en) * | 2002-09-26 | 2004-04-08 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
JP2004523582A (ja) * | 2001-03-15 | 2004-08-05 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼ阻害剤 |
WO2004093803A2 (en) * | 2003-04-16 | 2004-11-04 | Pintex Pharmaceuticals, Inc. | Photochemotherapeutic compounds for use in treatment of pin1-associated states |
-
2005
- 2005-11-14 TW TW094139843A patent/TW200626130A/zh unknown
- 2005-11-14 JP JP2006544994A patent/JPWO2006051937A1/ja not_active Withdrawn
- 2005-11-14 WO PCT/JP2005/020791 patent/WO2006051937A1/ja active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513821A (ja) * | 1997-03-03 | 2001-09-04 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 炎症性疾患の治療に有用な小分子 |
JP2004523582A (ja) * | 2001-03-15 | 2004-08-05 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼ阻害剤 |
WO2003006425A2 (en) * | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
WO2003030905A1 (fr) * | 2001-10-01 | 2003-04-17 | Shionogi & Co., Ltd. | Inhibiteur de la dihydroorotate deshydrogenase |
WO2004024061A2 (en) * | 2002-04-30 | 2004-03-25 | Merck & Co., Inc. | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
JP2004099586A (ja) * | 2002-05-21 | 2004-04-02 | Sumitomo Pharmaceut Co Ltd | ジヒドロオロテートデヒドロゲナーゼ阻害剤 |
WO2004028535A1 (en) * | 2002-09-26 | 2004-04-08 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
WO2004093803A2 (en) * | 2003-04-16 | 2004-11-04 | Pintex Pharmaceuticals, Inc. | Photochemotherapeutic compounds for use in treatment of pin1-associated states |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8686048B2 (en) | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
US9758474B2 (en) | 2010-05-06 | 2017-09-12 | Incozen Therapeutics Pvt. Ltd. | Immunomodulator and anti-inflammatory compounds |
WO2012109329A2 (en) | 2011-02-08 | 2012-08-16 | Children's Medical Center Corporation | Methods for treatment of melanoma |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006051937A1 (ja) | 2008-05-29 |
TW200626130A (en) | 2006-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6980734B2 (ja) | 心臓状態に対するピリミジンジオン化合物 | |
US9902701B2 (en) | Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection | |
WO2006038606A1 (ja) | ビアリール誘導体 | |
JP2007015952A (ja) | ナフタレン誘導体 | |
TWI481604B (zh) | Novel 5-fluorouracil derivatives | |
JP7368419B2 (ja) | アルドース還元酵素阻害剤およびその使用方法 | |
JP6008937B2 (ja) | 1−(3−シアノ−1−イソプロピル−インドール−5−イル)ピラゾール−4−カルボン酸の結晶形とその製造方法 | |
JPWO2018181883A1 (ja) | 4−ピリドン化合物またはその塩、それを含む医薬組成物および剤 | |
WO2006051937A1 (ja) | ヘテロ5員環誘導体 | |
TW200925154A (en) | Phenylacetic acid compound | |
US20170119795A1 (en) | Fused triterpene compounds and uses thereof | |
JP3539926B2 (ja) | 抗ウイルス性ピリミジンジオン誘導体及びそれらの製造方法 | |
JP2019524875A (ja) | 肝臓送達に基づく抗ウイルス性プロドラッグであるヌクレオシド環状リン酸エステル化合物およびその使用 | |
Li et al. | Arylazolyl (azinyl) thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors | |
JPWO2002057237A1 (ja) | 置換アミノ基を有するヘテロ3環化合物 | |
JP2009504652A (ja) | 非ヌクレオシド逆転写酵素阻害剤 | |
WO2004014873A1 (ja) | 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 | |
KR20230142739A (ko) | 피리미딘 유도체 | |
JPWO2003030905A1 (ja) | ジヒドロオロテートデヒドロゲナーゼ阻害剤 | |
US7179808B2 (en) | Substituted heteroaryl and heterocyclic compounds useful in treating inflammatory disorders | |
WO1991009847A1 (fr) | Derive d'ethynylphenyle, production de ce derive et medicament de traitement des maladies des organes du systeme circulatoire contenant ce derive comme ingredient actif | |
CN117343017A (zh) | 含联芳基结构的卤代二芳基嘧啶类化合物及其制备方法和用途 | |
JPWO2004024142A1 (ja) | Hsp90ファミリー蛋白質阻害剤 | |
WO2004005267A1 (en) | Heteroaryl compounds useful in treating inflammatory disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006544994 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05805963 Country of ref document: EP Kind code of ref document: A1 |